In agreement with our results, the expression of PD-L1 has predicted poor survival of breast cancer [9], esophageal cancer [10], pancreatic cancer [13], gastric cancer [14], hepatocellular carcinoma [15], urothelial cancer [16], and renal cell carcinoma patients [17]. This evidence concerns the gene CD274 and pancreatic neoplasm.